Janus kinase inhibitors for rheumatoid arthritis

Current Opinion in Chemical Biology

Volumn 32, Issue , 2016, Pages 29-33

  Yamaoka, Kunihiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BARICITINIB; BIOLOGICAL PRODUCT; JANUS KINASE; JANUS KINASE INHIBITOR; METHOTREXATE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; PROTEIN KINASE INHIBITOR;

COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; JANUS KINASES; PROTEIN KINASE INHIBITORS;

EID: 84960894417     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2016.03.006     Document Type: Review

References (44)

1. van der Heide A., Jacobs J.W., Bijlsma J.W., Heurkens A.H., van Booma-Frankfort C., van der Veen M.J., Haanen H.C., Hofman D.M., van Albada-Kuipers G.A., ter Borg E.J., et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996, 124:699-707.
2. Tanaka Y., Hirata S., Saleem B., Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013, 31:S22-S27.
3. Smolen J.S., Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015, 11:276-289.
4. D'Aura Swanson C., Paniagua R.T., Lindstrom T.M., Robinson W.H. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:317-324.
5. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V., Beroukas D., Roberts-Thomson P.J., Smith M.D. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006, 65:1558-1564.
6. Cha H.S., Boyle D.L., Inoue T., Schoot R., Tak P.P., Pine P., Firestein G.S. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006, 317:571-578.
7. O'Shea J.J., Kontzias A., Yamaoka K., Tanaka Y., Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013, 72(Suppl. 2):ii111-ii115.
8. Walker J.G., Ahern M.J., Coleman M., Weedon H., Papangelis V., Beroukas D., Roberts-Thomson P.J., Smith M.D. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006, 65:149-156.
9. Muller-Ladner U., Judex M., Ballhorn W., Kullmann F., Distler O., Schlottmann K., Gay R.E., Scholmerich J., Gay S. Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol 2000, 164:3894-3901.
10. Russell S.M., Tayebi N., Nakajima H., Riedy M.C., Roberts J.L., Aman M.J., Migone T.S., Noguchi M., Markert M.L., Buckley R.H., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800.
11. Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
12. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., Takada H., Hara T., Kawamura N., Ariga T., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006, 25:745-755.
13. Seto Y., Nakajima H., Suto A., Shimoda K., Saito Y., Nakayama K.I., Iwamoto I. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 2003, 170:1077-1083.
14. Schwartz D.M., Bonelli M., Gadina M., O'Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016, 12:25-36.
15. Clark J.D., Flanagan M.E., Telliez J.B. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014, 57:5023-5038.
16. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., Gruben D., Wallenstein G.V., Zwillich S.H., Kanik K.S., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012, 367:495-507.
17. Fleischmann R., Huizinga T., Kavanaugh A., Wilkinson B., Kwok K., DeMasi R., van Vollenhoven R. An analysis of the efficacy of tofacitinib monotherapy in MTX-naïve patients with early RA compared with patients with established RA. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 2741].
18. Wollenhaupt J.S.J., Lee E.B., Terry K., Kwok K., Lazariciu I., Nduaka C., Connell C.A., DeMasi R., Wang L. Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Arthritis Rheumatol 2015, 67(Suppl. 10).
19. Yamaoka K., Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother 2014, 15:103-113.
20. van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., Garcia Meijide J.A., Wagner S., Forejtova S., Zwillich S.H., Gruben D., Koncz T., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012, 367:508-519.
21. Kremer J., Li Z.G., Hall S., Fleischmann R., Genovese M., Martin-Mola E., Isaacs J.D., Gruben D., Wallenstein G., Krishnaswami S., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013, 159:253-261.
22. Lee E.B., Fleischmann R., Hall S., Wilkinson B., Bradley J.D., Gruben D., Koncz T., Krishnaswami S., Wallenstein G.V., Zang C., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014, 370:2377-2386.
23. He Y., Wong A.Y., Chan E.W., Lau W.C., Man K.K., Chui C.S., Worsley A.J., Wong I.C. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2013, 14:298.
24. Charles-Schoeman C., Dikranian A., Taylor J., Wilkinson B., Jones T., Kwok K., Nduaka C. Assessment of lipid changes in patients with early rheumatoid arthritis treated with tofacitinib or methotrexate over 24 months. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 487].
25. Strand V., Ahadieh S., French J., Geier J., Krishnaswami S., Menon S., Checchio T., Tensfeldt T.G., Hoffman E., Riese R., et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015, 17:362.
26. Wollenhaupt J., Silverfield J., Lee E.B., Curtis J.R., Wood S.P., Soma K., Nduaka C.I., Benda B., Gruben D., Nakamura H., et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014, 41:837-852.
27. Cohen S., Radominski S.C., Gomez-Reino J.J., Wang L., Krishnaswami S., Wood S.P., Soma K., Nduaka C.I., Kwok K., Valdez H., et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 2014, 66:2924-2937.
28. Winthrop K.L., Yamanaka H., Valdez H., Mortensen E., Chew R., Krishnaswami S., Kawabata T., Riese R. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014, 66:2675-2684.
29. Yawn B.P., Gilden D. The global epidemiology of herpes zoster. Neurology 2013, 81:928-930.
30. Souto A., Salgado E., Maneiro J.R., Mera A., Carmona L., Gomez-Reino J.J. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015, 67:117-127.
31. Charles-Schoeman C., Fleischmann R., Davignon J., Schwartz H., Turner S.M., Beysen C., Milad M., Hellerstein M.K., Luo Z., Kaplan I.V., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015, 67:616-625.
32. Moisan A., Lee Y.K., Zhang J.D., Hudak C.S., Meyer C.A., Prummer M., Zoffmann S., Truong H.H., Ebeling M., Kiialainen A., et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol 2015, 17:57-67.
33. Fridman J.S., Scherle P.A., Collins R., Burn T.C., Li Y., Li J., Covington M.B., Thomas B., Collier P., Favata M.F., et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010, 184:5298-5307.
34. Keystone E.C., Taylor P.C., Drescher E., Schlichting D.E., Beattie S.D., Berclaz P.Y., Lee C.H., Fidelus-Gort R.K., Luchi M.E., Rooney T.P., et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015, 74:333-340.
35. Genovese M.C., Kremer J., Zamani O., Ludivico C., Krogulec M., Xie L., Beattie S., Koch A.E., Cardillo T., Rooney T., et al. Baricitinib, an oral janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-BEACON study. Ann Rheum Dis 2015, 74(Suppl. 2):75.
36. Dougados M., van der Heijde D., Chen Y.-C., Greenwald M., Drescher E., Liu J., Beattie S., de la Torre I., Rooney T., Schlichting D., et al. Baricitinib, an oral janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to cDMARD therapy: results of the phase 3 RA-BUILD study. Ann Rheum Dis 2015, 74(Suppl. 2):79.
37. Fleischmann R., Takeuchi T., Schlichting D., Macias W., Rooney T., Gurbuz S., Stoykov I., Beattie S., Kuo W., Schiff M. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 1045].
38. Taylor P., Keystone E., van der Heijde D., Tanaka Y., Ishii T., Emoto K., Yang L., Arora V., Gaich C., Rooney T., et al. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 2L].
39. Jabbari A., Dai Z., Xing L., Cerise J.E., Ramot Y., Berkun Y., Sanchez G.A., Goldbach-Mansky R., Christiano A.M., Clynes R., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2015, 2:351-355.
40. Fleischmann R.M., Damjanov N.S., Kivitz A.J., Legedza A., Hoock T., Kinnman N. A Randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015, 67:334-343.
41. Genovese M.C., van Vollenhoven R.F., Pacheco-Tena C., Zhang Y., Kinnman N. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016, 68:46-55.
42. Kremer J., Keystone E., Emery P., Camp H., Friedman H., Wang L., Othman A., Khan N., Jungerwirth S. Safety and efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 14L].
43. Westhovens R., Alten R., Pavlova D., Enríquez-Sosa F., Mazur M., Greenwald M., Van der Aa A., Vanhoutte F., Tasset C., Harrison P. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 1048].
44. Hidaka Y., Nakamura T., Igarashi T., Nanya T., Hagiwara S., Takeuchi K., Yaguchi T., Kawakami Y., Naito T. NIP-565, a novel JAK1-selective inhibitor, for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2015, 67(Suppl. 10). [abstract 2547].